Physician profile
Brian Adrian
NPI 1508092305
$1,882.79
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $68.83 · 2021: $40.14 · 2022: $1,598.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,520.68 | 2022 | |
| Novo Nordisk INC | $108.89 | 2019-2020 | |
| Pfizer INC. | $59.92 | 2019-2022 | |
| Abbvie INC. | $59.18 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $43.50 | 2019-2020 | |
| Lilly USA, LLC | $28.38 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.45 | 2019 | |
| Allergan, INC. | $13.40 | 2020 | |
| Tandem Diabetes Care, INC. | $9.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Adrian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.